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Commentary
Animal feed is a broad term that, for   animals 
produced for human consumption (e.g., 
dairy and beef cattle, hogs, layer hens, broiler 
chickens, turkeys), includes a diet that is spe-
cific to an animal’s species, age, and produc-
tion stage, and may vary according to time of 
year and plant species grown (Forbes 2007). 
Feeds are often provided to food animals on a 
“free-choice” basis, which means that animals 
elect whether or not to eat the feed and how 
much of it to ingest. Feeds containing medi-
cally active ingredients, such as antibiotic and 
antiparasitic drugs or insecticides, that are 
fed on a “free-choice” basis, are designated 
free-choice medicated feeds (FCMF) by the 
U.S. Food and Drug Administration (FDA 
2010h). The FDA has approved 685 drugs for 
medicated feed, some of which are consumed 
on a free-choice basis (for product list in a 
searchable database, see FDA 2010d).
The FDA reported that 13.1 million kg 
of antimicrobial drugs were sold or distrib-
uted for use in food-producing animals in 
2009 (FDA 2010i). Many of the same anti-
biotics or classes of antibiotics used to treat 
clinical infections in humans are also used 
in industrial food animal production (IFAP) 
(McEwen and Fedorka-Cray 2002).
The use of FCMF in food animals has 
been associated with imprecise drug intake, 
leading to under- or overadministration 
of drugs (Figure 1) (Bogan and Marriner 
1983; Hall 2000; Toutain et al. 2010). 
Overadministration of drugs may lead to ani-
mal toxicity (Guardabassi and Kruse 2008; 
Hall 2000) and the presence of drug residues in 
meat or milk, although this is rare (Burch et al. 
2008). Underadministration or inconsistent 
administration of drugs may lead to animal 
treatment failure (Burch et al. 2008) or the 
emergence of antibiotic-resistant strains of 
microorganisms in food animals (Guardabassi 
and Kruse 2008; Khachatourians 1998; Lees 
et al. 2006). Antibiotic-resistant commensal 
and environmental bacteria can contribute 
to maintaining or perpetuating a reservoir of 
resistance genes (Chee-Sanford et al. 2009; 
Silbergeld et al. 2008; Wright 2007), and these 
bacteria can share genes for antibiotic resistance 
with pathogenic bacteria via horizontal gene 
transfer (Andremont 2000). Multiple resis-
tance genes travel on the same mobile genetic 
element (e.g., plasmid), allowing one phar-
maceutical to select for microorganisms that 
are resistant to multiple classes of antibiotics 
(Wright 2007). In addition to natural selection 
and horizontal gene transfer as mechanisms 
for resistance, sublethal bactericidal antibiotic 
use at doses below those expected to provide 
overt selective pressure induces mutations in 
bacterial genomes that may confer antibiotic 
resistance (Kohanski et al. 2010). Humans 
are exposed to anti  biotic-resistant bacteria 
through many pathways, including direct ani-
mal contact (Price et al. 2007a), contact with 
environmental media, such as soil, water, and 
air, contaminated with animal waste (Graham 
et al. 2009), and consumption or handling 
of contaminated food products from animals 
raised with antibiotics (FDA 2010e; Johnson 
et al. 2009).
Use of medicated feed has been demon-
strated to introduce residual antimicrobials 
and their metabolites into the waste streams 
of animal operations. As much as 75% of 
administered antibiotics (Chee-Sanford 
et al. 2009), and considerable fractions of 
some antiparasitic medications (Lumaret and 
Errouissi 2002; Wall and Strong 1987), are 
not absorbed by animals and are eliminated 
in waste. Some insecticides and antiparasitic 
drugs included in certain feed supplements 
are designed to be excreted by animals to 
control insects attracted to animal droppings 
(Wall and Strong 1987). These wastes con-
tribute to drug loads in watersheds and in 
other environmental media that may become 
available for human or nontarget organism 
exposure (Arikan et al. 2008; Chee-Sanford 
et al. 2009; Lumaret and Errouissi 2002). 
One route for drug exposure to humans is 
through food crops that take up anti  biotics 
when fertilized with animal manure con-
taining these same antibiotics (Kumar et al. 
2005). The human health consequences of 
exposures to these drugs and their metabolites 
at environmentally relevant concentrations 
remain largely uncharacterized.
The FDA regulates medicated feed (FDA 
2010a, 2010b) and in doing so separates ani-
mal drugs into two types: therapeutic drugs 
that are used to “diagnose, cure, mitigate, 
treat, or prevent disease in animals,” and ani-
mal production drugs that are intended only 
for healthy livestock and used to “enhance the 
production of edible or nonedible products or 
to increase the efficiency of a particular phase 
of life” to increase the rate of weight gain, 
improve feed efficiency, or enhance milk pro-
duction (Sechen 2006). Both types of drugs, 
by FDA regulation, can be sold without vet-
erinary prescription as medicated feed prod-
ucts (FDA 2000, 2010c). As part of the FDA 
approval, all medicated feed products are 
required to have labels listing active ingredi-
ents by medication name and concentration, 
indications for use, and all other ingredients 
by weight so that contents can be read and 
interpreted by workers at animal production 
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facilities. In some cases, a medicated feed is 
broadly labeled both for disease treatment 
of sick animals and for disease prevention or 
growth promotion in healthy animals.
The purpose of this commentary is to dis-
cuss the history of medicated feed, the nature of 
FCMF use, and its role in the development of 
antimicrobial-resistant microorganisms. We also 
discuss the past and current legislative efforts to 
address antimicrobial use in food animals.
A History of Medicated Feed
The rationale for including antibiotics in feed 
was constructed in the late 1940s and early 
1950s when studies began to report a correla-
tion between the use of antibiotics (mainly 
chlortetracycline and oxytetra  cycline) in live-
stock, swine, and poultry with increased rates 
of animal weight gain (Jones and Ricke 2003). 
The food animal production industry imple-
mented in-feed anti  biotic use in conjunction 
with high-throughput single-species cultiva-
tion to enhance production of grain-fed, feed-
lot livestock and poultry (Pew Commission 
on Industrial Farm Animal Production 2008). 
Antibiotic and anti  helminthic additives were 
included in mineral and other feed supple-
ments beginning in the early 1960s and 1970s, 
respectively (Hanson 1963). In 1960, the 
Agricultural and Medical Research Council 
Committee of Great Britain suggested that 
antibiotics offered economic advantages to 
livestock producers by lowering production 
costs (Kiser 1976).
Concerns were raised as early as the 1950s 
when researchers noted that antibiotic-resistant 
bacteria emerged when animals were adminis-
tered antibiotics (Finland 1956). The potential 
for adverse human health consequences result-
ing from low-level exposures to antibiotic 
residues in meat, milk, and eggs also was iden-
tified (Randall 1956). Apprehension regarding 
the use of human drugs in animals was noted 
in a 1969 European report, Use of Antibiotics 
in Animal Husbandry and Veterinary Medicine 
(Swann 1969). U.S. regulators addressed these 
concerns in a 1972 report by the FDA Task 
Force on the Use of Antibiotics in Animal 
Feeds (Van Houweling and Gainer 1978) and 
an FDA-proposed policy statement (Edwards 
1972). In 1972 and 1973, strong reaction 
against the proposed FDA policy statement 
from representatives of the livestock indus-
try, veterinary pharmaceutical manufacturers, 
and some animal science researchers prompted 
revision of the final 1974 policy to incorpo-
rate consideration of the value of antibiotics 
in animal feed for increased rate of gain, feed 
efficiency, and disease control (Gardner 1973; 
Kiser 1976). Industry groups have continued 
to influence the regulatory trajectory of poli-
cies surrounding the use of antimicrobials in 
food animal production.
Antimicrobial Dose Delivery 
by FCMF
Difficulties in ensuring precision in anti-
microbial dose delivery, a function of numer-
ous factors, may result in the inability to 
deliver predictable, uniform, or intended 
dose levels. These factors, although not mutu-
ally exclusive, can be grouped into concerns 
regarding labeling, veterinary oversight, feed 
characteristics, the behavior of animal produc-
tion facility workers, animal behavior, and 
drug pharmacokinetics.
Quality control of medicated feed. 
Requirements for quality control in manu-
facturing for antibiotics intended for use in 
animal finished feed products are less rigorous 
than those for pharmaceuticals intended for 
parenteral use in livestock or for human use 
(FDA 2009, 2010f, 2010g). Quality control 
problems can occur when drugs are combined 
with other feed ingredients. In an investiga-
tion of feeds labeled as nonmedicated, 44% 
(71 of 161) actually contained antimicrobials, 
and more than one-third (87 of 247) of feeds 
labeled as medicated contained undeclared 
antimicrobials, most notably chlortetracycline, 
sulfonamides, penicillin, and ionophores 
(Lynas et al. 1998). Investigators hypothesized 
that the presence of these unlabeled drugs 
was a result of cross-contamination in feed 
production mills. Quality control issues in 
animal feed content are not limited to those 
containing medication—a 2008 commer-
cial feed survey by the U.S. Department of 
Agriculture (USDA) found that nearly 20% 
(123 of 657) of animal feed products were 
mislabeled; their product ingredient claims 
were not sub  stantiated by an independent 
testing laboratory (USDA 2008).
The undeclared presence of medications 
in feed supplements results in the unintended 
delivery of antimicrobials and could compro-
mise the USDA organic certification status of 
food animal products. Allowance of antibiotic 
use in organic breeder stock (organic broiler 
chicks before and on the first day of hatching) 
as well as in herds used for cattle replacement 
of organic dairy cattle may undermine the 
spirit of USDA organic certification.
Animal production facility worker 
behavior. Because veterinary oversight or pre-
scription is not required to purchase, mix, 
or administer most medicated feed products 
(FDA 2000), workers at animal production 
facilities may be exclusively responsible for the 
decision to use medicated feed. Certain medi-
cated feeds are labeled to treat specific morbidi-
ties, for example, anaplasmosis or Pasteurella 
pneumonia (FDA 2010d). Such diseases often 
require clinical diagnosis and laboratory confir-
mation (Hartwig and Ensley 2010). Allowing 
workers to purchase medicated feed without 
a veterinary prescription to treat diseases that 
require a veterinarian to diagnose may result in 
drug administration in a manner inconsistent 
with its intended use.
Animal and herd behavior. The number of 
animals per feeding location or feed block, feed 
location within animal production facility, 
other housing or grazing area characteristics 
and herd or flock social interactions are fac-
tors shown to influence feed intake for rumi-
nants and poultry (Appleby 1998; Bowman 
and Sowell 1997, 2002; Kincheloe 2004). 
Interanimal dominance scenarios influence 
the quantity of feed consumed by ruminants 
Figure 1. Dose imprecision for food animals that consume FCMF and a pathway to antibiotic resistance. 
Overadministration leads to very high plasma or target tissue levels of antibiotic. Underadministration leads 
to levels of antibiotic that never reach minimum inhibitory concentrations (MICs). Intermittent dosing leads 
to levels of antibiotic that fluctuate and periodically dip below MICs for variable periods of time. ROS, reac-
tive oxygen species. Dotted lines indicate positive feedback, potentially driving increased use of FCMF.
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(Bowman and Sowell 2002), and in poultry, 
pecking order affects medicated feed intake, 
leading to differences in drug exposure among 
animals (Toutain et al. 2010). Acceptance of 
feed increases with animal age and prior expe-
rience with feed type (Bowman and Sowell 
1997; Kincheloe 2004). A fraction of live-
stock herds refuse FCMF; these animals were 
shown to have low serum and plasma concen-
trations of drugs (Bogan and Marriner 1983). 
Administering medication via FCMF is not 
an efficient way to achieve accurate serum and 
plasma concentrations of drugs across a herd 
or flock of animals.
Nondomesticated animals. When FCMF 
are freely available to livestock, they may be 
available to wildlife living on or near animal 
production operations. Studies in Europe and 
the United States have demonstrated that 
antibiotic-resistant bacteria can be found in 
feral hogs and other wildlife (Costa et al. 2008; 
Literak et al. 2010; Ramlachan et al. 2007). 
Wildlife living on farms are more likely to har-
bor antibiotic-resistant Escherichia coli than 
wildlife not living on farms (Kozak et al. 2009). 
Although exposure to feed may explain transfer 
of resistant bacteria to wildlife, other possible 
production-related pathways of exposure exist, 
including contact with contaminated manure, 
dust, or water. Wildlife movement from 
the source farm rarely is restricted and can 
spread antimicrobial-resistant microorganisms 
and diseases to other communities or farms 
(Ramlachan et al. 2007; Ward et al. 2006).
Drug absorption, pharmacokinetics, and 
pharmacodynamics. After drug consump-
tion, factors that influence absorption and 
pharmaco  kinetics determine target organ dose 
(Lees et al. 2006). Some drugs given orally, 
such as tetracyclines, may bind to cations (e.g., 
calcium) that are found in feed, lowering their 
bioavailability and resulting in serum concen-
trations below minimum inhibitory concen-
trations, even in animals dosed at levels for 
disease treatment (Nielsen and Gyrd-Hansen 
1996; Underhill and Danish 1992). Proteins, 
carbohydrates, and fats present in feeds also 
may alter absorption of many drugs (Underhill 
and Danish 1992). Commensal bacteria pres-
ent in the rumen of cows may chemically 
alter drugs administered orally (Then 1982). 
Finally, disease states alter an animal’s abil-
ity to absorb and process drugs for systemic 
delivery (Guardabassi and Kruse 2008). Fever, 
concurrent organ damage (e.g., hepatic lipido-
sis in dairy cows), and gastrointestinal disease 
may influence the final serum concentrations 
of a drug (Kozak et al. 2009; Underhill and 
Danish 1992). This is of particular concern 
when medications in feed supplements are 
licensed for disease treatment; the animals 
most in need of a drug may be the ones least 
likely or able to access doses consistent with 
disease treatment.
Taken in sum, numerous factors influence 
the ability to deliver predictable or intended 
doses of drugs to animals via FCMF. Given 
the limited oversight, the availability of FCMF 
without a veterinary prescription, the poten-
tial for undeclared drugs, and variability in 
drug concentrations within and between feeds, 
unintended (and therefore inappropriate) drug 
delivery is likely. At a minimum, these factors 
make predicting the actual delivered dose to 
any given individual animal nearly impossible 
and predicting herd averages for drug delivery 
complicated. Worse, inappropriate or impre-
cise drug dosing may drive selection for resis-
tant micro  organisms (Lees et al. 2006), that 
affect both veterinary and human medicine.
Policy Considerations
U.S. federal legislation. Elimination of anti-
biotics for growth promotion and feed effi-
ciency in IFAP in the United States has been 
discussed since the 1970s. The latest anti  biotics 
bill was reintroduced by Congresswoman 
Louise Slaughter (D-NY) in 2009 as the 
Preservation of Antibiotics for Medical 
Treatment Act (PAMTA; H.R.1549/S. 619, 
2009). PAMTA would withdraw federal 
approval for use of certain drugs as feed or 
water additives in food animal production if 
they are used for growth promotion, feed effi-
ciency, or weight gain, and for disease pre-
vention in the absence of any clinical sign of 
disease in an animal. A former head of the 
FDA, Donald Kennedy, called for Congress 
to pass PAMTA (Kennedy 2010). Passage of 
the bill would not affect the use of insecti-
cides (e.g., tetrachlorvinphos or methoprene) 
or antiparasitic drugs (e.g., thiabendazole) in 
medicated feeds that are fed for therapeutic 
uses, or antiparasitic drugs for nontherapeutic 
uses. Although regulating the use of antipara-
sitics and insecticides is relevant to the ecol-
ogy of drug resistance, these drugs are more 
appropriate for oral dosing using herd health 
management methods. Some evidence sup-
ports efficacy of antiparasitics, insecticides, and 
certain antibiotics in particular species via feed 
supplement administration (Blagburn et al. 
1987; McBride et al. 2008).
Although PAMTA begins to address these 
concerns, more effort is needed to reform the 
conventional (nonorganic) U.S. dairy, beef cat-
tle, hog, and poultry industries. In Denmark, 
swine and poultry productivity stabilized and, 
in some cases, increased after bans on non-
therapeutic uses of certain antibiotics during 
the late 1990s (Aarestrup 2009; Lawson et al. 
2008). Denmark monitors the veterinary 
use of antimicrobial drugs for IFAP through 
VETSTAT, a transparent data reporting sys-
tem that tracks compliance of legislation, helps 
veterinarians work with animal production 
facility workers, and provides data for research 
on veterinary drugs (Stege et al. 2003). In the 
United States, no federal requirements cur-
rently exist for reporting animal antimicrobial 
drug use by animal production facility staff or 
veterinarians, although in a historic move, the 
FDA began reporting annual antimicrobial 
drug distribution and sales summary data in 
2010 as required by the 2008 reauthoriza-
tion of the Animal Drug User Fee Act (FDA 
2010i). If these data are made publically avail-
able in a timely fashion and usable format, 
then an assessment of the extent of anti  biotic 
use in IFAP can be conducted. Although 
reporting itself will not mitigate anti  microbial 
resistance risks, understanding the extent, 
nature, and distribution of antimicrobial use 
in IFAP will strengthen the impetus for policy 
interventions aimed at eliminating unnecessary 
administration of antimicrobials.
U.S. federal regulatory agency involvement.   
Human cases of fluoroquinolone-resistant, 
food-borne Campylobacter increased after 
the licensing of fluoroquinolones for use 
in poultry during the 1990s (Gupta et al. 
2004; Nelson et al. 2007). As a result, the 
FDA withdrew approval for fluoroquinolone 
use in water to treat diseases in poultry in 
2005 in response to concerns over agricul-
tural drivers of resistant infections in humans 
(Gupta et al. 2004; Nelson et al. 2007). Even 
after the fluoro  quinolone ban, bacterial resis-
tance persisted in poultry products (Price 
et al. 2007b), highlighting the importance 
of early action to remove nontherapeutic use 
of antibiotics in livestock. In 2010, the FDA 
issued a draft guidance over concerns with 
antimicrobial use, stating that “the overall 
weight of evidence available to date supports 
the conclusion that using medically impor-
tant antimicrobial drugs for production pur-
poses is not in the interest of protecting and 
promoting the public health” (FDA 2010j). 
However, as guidance, the FDA document is 
not binding or enforceable.
Conclusion
Delivering antibiotics to food animals for 
reasons other than treatment of clinically 
diagnosed disease, especially via free-choice 
feeding methods, poses an unnecessary pub-
lic health risk. Mounting evidence suggests 
the use of antibiotics in food animal produc-
tion contributes to a considerable fraction 
of antibiotic-resistant infections in humans 
(Silbergeld et al. 2008). The increasing num-
ber of antimicrobial-resistant infections and 
their costs in the United States, estimated to 
be $400 million to $5 billion per year in 1998 
(Institute of Medicine 1998) and $16.6 to $26 
billion per year in 2009 (Roberts et al. 2009), 
are of growing concern. Methicillin-resistant 
Staphylococcus aureus (MRSA) infections 
acquired outside of hospitals (i.e., community-
associated MRSA) have seen a 33% annual 
increase from 1999 to 2006 (Klein et al. Love et al.
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2009). Although not all community-associated 
MRSA infections originate from IFAP, certain 
human cases have been associated with the 
production of swine, poultry, and dairy cattle 
in Europe (Broens et al. 2008), and the poten-
tial for similar exposure pathways exists in the 
United States. Human exposures to antibiotic- 
resistant Campylobacter, Salmonella, and 
other resistant bacteria via food animal prod-
ucts are also of concern (Angulo et al. 2004; 
Kassenborg et al. 2004; Price et al. 2005).
Instead of farming practices that employ 
free-choice oral herd or flock dosing with medi-
cated feed, appropriate individual therapeu-
tic antimicrobial administration by injection 
should be pursued to treat clinically diagnosed 
disease in food animals. Therapeutic treatment 
by injection will achieve more predictable 
plasma drug levels, enhancing opportunities for 
disease control (Baggot 2007; Lees et al. 2006). 
In cases where individual treatment is difficult, 
such as with large poultry operations, improv-
ing husbandry and hygiene at production facil-
ities are preferred over the administration of 
oral therapeutic antimicrobial with veterinary 
supervision, and all are preferable to FCMF 
without veterinary supervision. For preven-
tion of diseases in a herd or flock, vaccinations 
(Redding and Weiner 2009), reduced stress 
(Dantzer and Mormède 1983), and improved 
welfare (Broom 2006) are approaches that can 
help replace antimicrobials.
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